2 terminated, 1 active not recruiting. 3 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Terminated 2, Active not recruiting 1 |
| Phase 2 | 2 | Active not recruiting 1, Terminated 1 |
Follow PMM2-CDG: new trials by email Literature Review of PMM2-CDG trials Research Report on PMM2-CDG
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess the Efficacy and Safety of Weekly Doses of GLM101 in Participants With PMM2-CDG GLM101 (Part A, Double-blind), Placebo (Part A, Double-blind), GLM101 (Part B, Open-label) - Phosphomannomutase 2 Deficiency, PMM2-CDG | Phase 2 / Phase 3 | Active not recruiting | Glycomine, Inc. | 50 | 2025-07-09 | 2026-08-14 |
| Oral Epalrestat Therapy in Pediatric Subjects With PMM2-CDG Epalrestat, Placebo - Pmm2-CDG, Phosphomannomutase 2 Deficiency | Phase 3 | Terminated | Maggie's Pearl, LLC | 42 | 2022-11-10 | 2025-09-25 |
| Acetazolamide Efficacy in Ataxia in PMM2-CDG Placebo, Acetazolamide - Pmm2-CDG, CDG1A | Phase 2 / Phase 3 | Terminated | Mayo Clinic | 25 | 2021-03-17 | 2025-03-20 |
Congenital disorder of glycosylation type 1A (3) · Ataxia (1)
Dyskinesias (1) · Nervous System Diseases (1) · Neurologic Manifestations (1) · Pathological Conditions, Signs and Symptoms (1) · Signs and Symptoms (1)
Acetazolamide (1) · Double-Blind Method (1) · Gelatin (1) · Lactose (1) · epalrestat (1)
Glycomine, Inc. (1) · Maggie's Pearl, LLC (1) · Mayo Clinic (1)
United States (3) · Belgium (1) · Czechia (1) · France (1) · Germany (1) · Italy (1) · Poland (1) · Portugal (1) · Spain (1) · United Kingdom (1)